How profitable is Oramed Pharmaceuticals Inc. (ORMP)?

In FY 2025 (10-K), ORMP converted $2.0M of revenue into a 0.7% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / ORMP / financials

ANTX (43) SION (33) ADAG (25) TRDA (16) ⌘ Pro Terminal →

Oramed Pharmaceuticals Inc. (ORMP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$4.00 -2.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.97

Oramed Pharmaceuticals Inc. (ORMP) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $171.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ORMP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ORMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $4.00 (-2.68% 1D, market cap $171.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ORMP ranks #684 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ORMP compare to ANTX and SION in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORMP carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 0.7%, and ROIC of -7.8%. By comparison, ANTX (AN2 Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $170.9M) and SION (Sionna Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -28.3%, cap $175.0M). Among the 5-stock peer group, ORMP leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ORMP?

▼

Per ORMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001176309), Oramed Pharmaceuticals Inc. generated $2.0M in revenue (-94.4% YoY), $75.3K in net income, and -$9.2M in free cash flow against $230.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.97 (-0.67%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ORMP)Realized 20D OHLCV Swing Band: ±7.6%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY ORMP SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 57% of 52W Range • RSI-14 at 40.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.17-0.5% Next Q

Q2 (-2Q)

Grade E$4.15+0.2% Next Q

Q3 (-1Q)

Grade E$4.16-3.8% Next Q

Current

Grade E$4.00-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ORMP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ORMP currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.54) and Max Pain ($4.20) forces dealer call-delta covering toward $5.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ORMP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ORMP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ORMP Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.3M

FY24

Rev $35.8M

FY25

Rev $2.0M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$2.0M	0.7%	-80%	$75.3K	-$9.2M	-7.8%
FY 2024	$35.8M	8%	-35.7%	-$15.9K	-$8.4M	-11%
FY 2023	$1.3M	8%	-80%	$5.1K	-$10.3M	-7.8%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ORMP)

✓Walkthrough of ORMP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ORMP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.78%🛡️ HOLDING TREND SUPPORT

2026-11-03O $4.23H $4.23L $4.00C $4.00VOL 91.5K

RES: $5.77SUP: $3.89SMA50: $4.54SMA200: $4.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ORMP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ORMP Butterfly Map → + Track ORMP →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -94.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ORMP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ORMP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ORMP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ORMP)

Health Care Rank #684 of 1015 ⚔️ ANTX vs ORMP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ORMP vs. ANTX, SION, ADAG, TRDA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Oramed Pharmaceuticals Inc. (ORMP) ranks #684 by composite RQD confidence (33/100, grade E) and #593 by equity capitalization ($171.0M). Within this direct 5-issuer industry benchmark cohort, ORMP leads on earnings valuation at N/A trailing P/E, while ORMP leads on capital efficiency and profitability with -7.8% ROIC and 0.7% gross margin. ANTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ORMP at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ORMP ACTIVE Oramed Pharmaceuticals Inc.	E	33/100	—	0.7%	-7.8%	-2.68%	$171.0M	Benchmark Subject
ANTX AN2 Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.97%	$170.9M	/antx-vs-ormp →
SION Sionna Therapeutics Inc.	E	33/100	—	—	-28.3%	-3.62%	$175.0M	/sion-vs-ormp →
ADAG Adagene Inc.	E	25/100	—	—	-35.0%	-8.76%	$165.8M	/adag-vs-ormp →
TRDA Entrada Therapeutics Inc.	E	16/100	—	—	-35.0%	+12.68%	$176.6M	/trda-vs-ormp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001176309 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Oramed Pharmaceuticals Inc. (ORMP) reported GAAP revenue of $2.0M (-94.4% vs. FY2024 revenue of $35.8M , and +49.3% cumulative change since FY2023) , GAAP net income of $75.3K, operating cash flow of -$9.1M, and free cash flow of -$9.2M (-8.6% YoY). On the balance sheet, ORMP closed FY2025 with $230.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.0M	$75.3K	-$9.1M	-$9.2M	$230.9M	—
FY2024 (FY)	2024-12-31	$35.8M	-$15.9K	-$8.4M	-$8.4M	$155.3M	—
FY2023 (FY)	2023-12-31	$1.3M	$5.1K	-$10.3M	-$10.3M	—	—

3. ORMP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ORMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ORMP compare to ANTX and SION in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ORMP?

Where is ORMP trading relative to its 50-day, 200-day, and 52-week technical levels?

ORMP last traded at $4.00 (-2.68% on volume of 97,267 shares), positioning the stock -11.89% below its 50-day simple moving average ($4.54) and -0.99% below its 200-day simple moving average ($4.04). Across its 52-week range of $2.09 to $5.47, ORMP sits at the 56.5% percentile with a 14-day RSI of 40.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.6% ($3.70 to $4.30).

Direct Sub-Reports: ORMP RQD Cockpit ORMP 12M Forecast ORMP Earnings & Move ORMP Dividends & DRIP ORMP Insiders & 13F ORMP Whale Options ORMP Profit Sankey ORMP News & Why

ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

ORMP — Oramed Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Oramed Pharmaceuticals Inc. (ORMP) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.00 (-2.68% 1D, market capitalization $171.0M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -7.8%, gross margin of 0.7%, operating margin of -60.0%, and free cash flow yield of -5.20%.
Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (ORMP) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Reported revenue in the SEC financials is $2.0M for FY 2025, — for FY 2024, and $1.3M for FY 2023. Market capitalization is listed as $0.2B in the profile and $176.0M in market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Oramed Pharmaceuticals Inc. (ORMP) reported $2.0M in annual revenue (up from $35.8M in FY2024, -94.4% YoY) and $75.3K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.3M revenue, $5.1K net income) through FY2025, ORMP scaled operating cash flow to -$9.1M and free cash flow to -$9.2M, backed by $230.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.20% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $2.09 – $5.47 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be assessed from the provided data beyond the sector classification (Health Care) and industry classification (Biotechnology: Pharmaceutical Preparations). A prospective investor should note that the absence of mapped links means this analysis cannot identify ripple effects from this graph.

Key Question #1: Can ORMP sustain or expand its -60.0% operating margin and -7.8% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $2.0M and free cash flow of -$9.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ORMP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ORMP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Oramed Pharmaceuticals Inc. (ORMP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ORMP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 23h ago

Oramed Pharmaceuticals Inc. (ORMP) Seasonal Returns Chart

Yahoo! Finance Canada report covering Oramed Pharmaceuticals Inc. (ORMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Oramed Pharmaceuticals (ORMP) Slips 2.63% to $4.07 as Shares Test Lower Support Zone - Bull Pennant

https://www.siam.in/ report covering Oramed Pharmaceuticals Inc. (ORMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Oramed Pharmaceuticals schedules November 12 results for Oramed Pharmaceuticals stock

ad-hoc-news.de report covering Oramed Pharmaceuticals Inc. (ORMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Entera Bio Ltd. (ENTX) Seasonal returns chart

Yahoo Finance UK report covering Oramed Pharmaceuticals Inc. (ORMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Oramed Pharmaceuticals stock at EUR 3.78 in late quote

ad-hoc-news.de report covering Oramed Pharmaceuticals Inc. (ORMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 67d ago

ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness

By M. Marin NASDAQ: ORMP READ THE FULL ORMP RESEARCH REPORT Gains on investment portfolio + service agreement income contributed to 2Q26 EPS of $2.76 Oramed Pharmaceuticals (NASDAQ: ORMP) leverages its strong balance she

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 138d ago

ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community

By M. Marin NASDAQ: ORMP READ THE FULL ORMP RESEARCH REPORT ORMP shares to be added to the Russell 2000® & Russell 3000® As Oramed Pharmaceuticals (NASDAQ: ORMP) transitions its business model to leverage its strong bala

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 139d ago

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

Yahoo Finance coverage on ORMP stock catalysts, institutional flow, and earnings outlook.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ORMP Bull vs. Bear Conversation Board — What's Your Call at $4.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ORMP 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $5.38 (+30.9%)

📌 Pinned Debate

Reported cash of $45.9M and a mid-range Altman Z-Score of 2.5 provide a balance-sheet buffer against ongoing free-cash-flow losses of $

Don't sleep on ORMP's setup in Health Care. Reported cash of $45.9M and a mid-range Altman Z-Score of 2.5 provide a balance-sheet buffer against ongoing free-cash-flow losses of -$9.2M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (33/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.7%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $3.37 (-18.0%)

Spot @ $4.11

Operating income of -$15.1M, negative ROIC of -7.8%, and an insider-conviction pillar score of 3 / 20 indicate weak cash generation and

Fading this rally in ORMP at $4.11. Operating income of -$15.1M, negative ROIC of -7.8%, and an insider-conviction pillar score of 3 / 20 indicate weak cash generation and limited insider support.. With a beta of 1.0 and the stock sitting at $4.11 (52-wk range $2.09–$5.47), the easy multiple expansion is already priced in.